Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030

Making predictions about how stocks will perform is easy. Predicting with any significant degree of accuracy, on the other hand, is extremely hard.I think that's especially true with biotech stocks. It's impossible to know which pipeline programs will flop or succeed beyond investors' wildest dreams. Despite these obstacles, I'm going to step out on a limb and make a prediction: These could be the best-performing biotech stocks through 2030, listed alphabetically and limited to biotech stocks that already have market caps of at least $5 billion.You might be surprised to see Moderna (NASDAQ: MRNA) on my list. Its share price has plunged over 30% this year. Moderna is roughly 86% below its peak set in 2021. However, I think this beaten-down biotech stock could realistically be one of the biggest winners through the rest of the decade.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool